Action KURA KURA ONCOLOGY, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Kura Oncology, Inc.

Actions

KURA

US50127T1097

Marché Fermé - Nasdaq
Autres places de cotation
 19:00:00 03/07/2024 		Varia. 5j. Varia. 1 janv.
20,06 USD -2,53 % Graphique intraday de Kura Oncology, Inc. -2,62 % +39,50 %
24/05 Kura Oncology, Inc. Complète le recrutement de 85 patients dans la portion phase 2 de KOMET-001 CI
15/05 Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Kura Oncology : Corporate Presentation June 2024
PU
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
AQ
Kura Oncology : Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive Awards Form 8 K
PU
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Kura Oncology to Participate in Jefferies Global Healthcare Conference
AQ
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
AQ
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
AQ
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Kura Oncology : Corporate Presentation - May 2024
PU
Kura Oncology: Q1 Earnings Snapshot
AQ
Kura Oncology Reports First Quarter 2024 Financial Results
AQ
Kura Oncology to Report First Quarter 2024 Financial Results
AQ
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
AQ
Kura Oncology to Participate in Stifel Targeted Oncology Forum
AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
AQ
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Kura Oncology: Q4 Earnings Snapshot
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action KURA
  4. Actualités Kura Oncology, Inc.
  5. Communiqués